Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-PEG-D3
- Development stage
- Preclinical
- Lead developer
- Boston Children's Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-PEG-D3 is a radiolabeled nanobody-based positron emission tomography (PET) imaging agent developed by researchers at Boston Children's Hospital and Harvard Medical School. It consists of the idiotype-specific nanobody clone D3, which is site-specifically sortase-conjugated to the chelator deferoxamine-polyethylene glycol (DFO-PEG) and labeled with the positron-emitting radioisotope zirconium-89 (89Zr). The nanobody D3 specifically targets the 2D2 T-cell receptor (TCR) idiotype, which is expressed on myelin oligodendrocyte glycoprotein (MOG)-specific CD4+ T cells. Autoreactive MOG-specific T cells are key drivers of neuroinflammation and demyelination in multiple sclerosis (MS). By binding to the 2D2 TCR, 89Zr-DFO-PEG-D3 enables non-invasive, high-contrast, longitudinal PET imaging of antigen-specific T cells in vivo, allowing researchers to monitor T-cell homing to secondary lymphoid organs and infiltration into the central nervous system in experimental autoimmune encephalomyelitis (EAE) models.
- Other names
- 89Zr-DFO-PEG-D3 nanobody89Zr-labeled DFO-PEG-D3
Beyond the preview
Go deeper on 89Zr-DFO-PEG-D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-PEG-D3.